This South American, phase 2/3 clinical trial will enable Immunophotonics to further advance the investigation of inCVAX, which is intended to be a specific, systemic, and targeted immuno-oncology treatment for metastatic tumors
Johnson & Johnson Inc. (NYSE: JNJ) opened the doors March 2 on its JLabs @ TMC with Immunophotonics as an initial member. As a member of JLabs, Immunophotonics has access to the company's 34,000-square-foot working space, which includes: 14 common spaces, 22 private labs, two concept or shared labs with 32 workstations, 34 offices and 32 workstations, and a prototype lab.
Immunophotonics, a St. Louis-based biotech startup, has added two executives to its team to help further advance its mission to develop a vaccine for cancer.
The startup, which moved to St. Louis from Columbia, Missouri, in 2013 after the company received a non-equity $50,000 grant from Arch Grants, hired Dr. Joe Raker as its first Chief Drug Development Officer and Dr. Siu Kit "Samuel" Lam as its Vice President of Science and Research.
Immunophotonics, a St. Louis-based biotech startup that has its eye on curing cancer, has completed a $1.8 million Series A financing round led by a group of local investors that include Cultivation Capital and the BioGenerator.